A New Chapter for Inherited Retinal Disease Gene Therapy: Opus Genetics Emerges

In a significant development for the inherited retinal disease (IRD) community, Ocuphire Pharma, Inc. has announced its acquisition of Opus Genetics, Inc. in an all-stock transaction. This merger, which took effect on October 23, 2024, will see the combined entity operate under the name Opus Genetics, Inc. and its shares began trading on Nasdaq under the ticker symbol "IRD" on October 24, 2024.

This strategic move is particularly impactful for patients and families affected by IRDs, as it establishes a clinical-stage company with a dedicated focus on advancing gene therapies for these rare conditions. The new Opus Genetics aims to be a leader in the development of gene therapies for inherited retinal degenerations.

Key Facts from the Acquisition:

  • New Identity: The combined company will be renamed Opus Genetics, Inc. and will trade on Nasdaq under the ticker symbol "IRD".
  • Leadership: George Magrath, M.D., previously CEO of Ocuphire, will continue as CEO of the combined company. Ben Yerxa, Ph.D., former President and CEO of Opus Genetics, will serve as President of the new entity. Scientific co-founder of Opus, Jean Bennett, M.D., Ph.D., will join the board of directors.
  • Pipeline Focus: The acquisition significantly strengthens the company's pipeline, which now includes multiple adeno-associated virus (AAV)-based gene therapies specifically for IRDs. These therapies target mutations in genes causing various forms of Leber congenital amaurosis (LCA), retinitis pigmentosa (RP), and bestrophinopathies.
  • Lead Programs: Central to the pipeline is OPGx-LCA5, a lead candidate for LCA5-related early-onset retinal degeneration. New six-month data from a Phase 1/2 trial showed visual improvement in all three adult patients with advanced disease. The OPGx-LCA5 program has received Rare Pediatric Disease, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT) FDA designations.
  • Financial Outlook: The combined company is projected to have a cash runway extending into 2026.

What This Means for Patients and Families:

This merger represents a consolidation of resources and expertise, aiming to accelerate the development of much-needed treatments for inherited retinal diseases. By focusing on gene therapies, the new Opus Genetics is directly addressing the underlying genetic causes of these conditions. The early positive data from the OPGx-LCA5 program, showing visual improvement in patients with advanced disease, offers a beacon of hope for individuals living with severe forms of IRDs. The company's commitment to advancing several programs, with clinical milestones anticipated in 2025, suggests a proactive approach to bringing potential therapies closer to patients.

Looking Forward:

The newly formed Opus Genetics is poised to continue its work in developing transformative therapies for IRDs. The company expects to announce several clinical milestones in 2025, including additional data from the OPGx-LCA5 study and clinical readouts from the OPGx-BEST1 gene therapy program for bestrophinopathies. This dedicated focus on gene therapy development, supported by an experienced leadership team, signals a promising future for the IRD community.